Work

Efficacy and safety of elinzanetant for vasomotor symptoms associated with adjuvant endocrine therapy: Phase 3 OASIS 4 trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.508

Authors: Fatima Cardoso, Donal J. Brennan, Paula Briggs, Gilbert Donders, Nick Panay, Nazanin Haseli Mashhadi, Cecilia Caetano, Maja Franscuski, Claudia Haberland, Kaisa Laapas, Christian Seitz, Lineke Zuurman

Institutions: University College Dublin, Liverpool Women's Hospital, Queen Charlotte's and Chelsea Hospital, Bayer (United Kingdom), Bayer (Switzerland), Bayer (Germany), Bayer (Finland)

Language: English

Topic: Menopause: Health Impacts and Treatments

Subfield: Endocrinology, Diabetes and Metabolism

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410810976

Cites:

Cited by: 2

Related to: 10